Title:
COMBINATION DRUG
Document Type and Number:
WIPO Patent Application WO/2023/022235
Kind Code:
A1
Abstract:
The present invention discloses administering a trinapant-type-drug-containing pharmaceutical composition in combination with a pharmaceutical composition that contains immune cells modified to express chimeric antigen receptors or recombinant T-cell receptors.
Inventors:
SONE MASAYUKI (JP)
MATSUYAMA HIRONORI (JP)
TAZURU KEISUKE (JP)
KOGUE YOSUKE (JP)
AKAMINE HIROKI (JP)
SUDO TOSHIKI (JP)
MATSUYAMA HIRONORI (JP)
TAZURU KEISUKE (JP)
KOGUE YOSUKE (JP)
AKAMINE HIROKI (JP)
SUDO TOSHIKI (JP)
Application Number:
PCT/JP2022/031444
Publication Date:
February 23, 2023
Filing Date:
August 19, 2022
Export Citation:
Assignee:
OTSUKA PHARMA CO LTD (JP)
International Classes:
A61K31/5377; A61K35/17; A61P35/00; A61P43/00
Domestic Patent References:
| WO2021202801A1 | 2021-10-07 | |||
| WO2015092420A1 | 2015-06-25 | |||
| WO2017026331A1 | 2017-02-16 | |||
| WO2008153029A1 | 2008-12-18 | |||
| WO1993019163A1 | 1993-09-30 |
Foreign References:
| JP2019504026A | 2019-02-14 | |||
| US4694778A | 1987-09-22 | |||
| US20180230212A1 | 2018-08-16 | |||
| US20180230216A1 | 2018-08-16 |
Other References:
XIAO ROY C A, CLINT ALLEN1,3, LINDA TRAN1 , SO-JIN PARK1 , ZHONG CHEN1 , CARTER VAN WAES1 , NICOLE SCHMITT1: " P289 Dual cIAP1/XIAP inhibitor ASTX660 synergizes with radiation therapy and PD-1 blockade to enhance anti-tumor immunity.", JOURNAL FOR IMMUNOTHERAPY OF CANCER, BIOMED CENTRAL, LONDON, GB, 8 November 2017 (2017-11-08), GB , pages 148, XP093036630, ISSN: 2051-1426
YE WENDA, GUNTI SREENIVASULU, ALLEN CLINT T., HONG YOUJI, CLAVIJO PAUL E., VAN WAES CARTER, SCHMITT NICOLE C.: "ASTX660, an antagonist of cIAP1/2 and XIAP, increases antigen processing machinery and can enhance radiation-induced immunogenic cell death in preclinical models of head and neck cancer", ONCOIMMUNOLOGY, vol. 9, no. 1, 1 January 2020 (2020-01-01), XP093036636, DOI: 10.1080/2162402X.2019.1710398
ROY XIAO, CLINT T. ALLEN, LINDA TRAN, PRIYA PATEL, SO-JIN PARK, ZHONG CHEN, CARTER VAN WAES, NICOLE C. SCHMITT: "Antagonist of cIAP1/2 and XIAP enhances anti-tumor immunity when combined with radiation and PD-1 blockade in a syngeneic model of head and neck cancer", ONCOIMMUNOLOGY, vol. 7, no. 9, 2 September 2018 (2018-09-02), pages e1471440, XP055526649, DOI: 10.1080/2162402X.2018.1471440
"The non-peptidomimetic cIAP1/2 and XIAP antagonist ASTX660 promotes an anti-tumour immune response in T-cell lymphoma", EUROPEAN JOURNAL OF CANCER, vol. 138, no. Suppl. 2, 2020, pages S28, XP086321408, DOI: 10.1016/S0959-8049(20)31141-2
MASAHIRO TSUJI // KEISHI ADACHI, KOJI TAMADA: "R & D initiative : new drug modality “Designer cell" // The novel strategies for CAR-T cell therapy targeting solid cancers", EXPERIMENTAL MEDICINE, YODOSHA CO., LTD., JP, vol. 38, no. 17, Suppl., 1 November 2020 (2020-11-01), JP , pages 25 - 34, 107-121, XP009543530, ISSN: 0288-5514
HO SEN NAOKI: "9. CAR-T Cell Therapy", EXPERIMENTAL MEDICINE SPECIAL EDITION, JP, vol. 37, no. 15, 13 September 2019 (2019-09-13), JP, pages 164 (2556) - 169 (2561), XP009543529, ISSN: 0288-5514
JESSICA MICHIE, ET AL.: "Antagonism of IAPs Enhances CAR T-cell Efficacy", CANCER IMMUNOLOGY RESEARCH, AMERICAN ASSOCIATION FOR CANCER RESEARCH, US, vol. 7, no. 2, 1 February 2019 (2019-02-01), US , pages 183 - 192, XP055632337, ISSN: 2326-6066, DOI: 10.1158/2326-6066.CIR-18-0428
FERRARI NICOLA, WARD GEORGE, GEWINNER CHRISTINA, DAVIS MATTHEW P., JUELIGER SIMONE, SAINI HARPREET, MUNCK JOANNE, SMYTH TOMOKO, FE: "Antagonism of inhibitors of apoptosis proteins reveals a novel, immune response-based therapeutic approach for T-cell lymphoma", BLOOD ADVANCES, vol. 5, no. 20, 26 October 2021 (2021-10-26), pages 4003 - 4016, XP093036700, ISSN: 2473-9529, DOI: 10.1182/bloodadvances.2020003955
SCIENCE, vol. 242, 1988, pages 1038 - 1041
NATURE, vol. 338, 1989, pages 54454 - 384
MOLECULAR IMMUNOLOGY, vol. 34, no. 16-17, 1997, pages 1157 - 1165
NATURE MEDICINE, 23 December 2007 (2007-12-23), pages 1436
J IMMUNOL., vol. 162, no. 2, 1999, pages 897 - 902
MOL CANCER THER., vol. 17, no. 7, July 2018 (2018-07-01), pages 1381 - 1391
ONCOIMMUNOLOGY, vol. 9, no. 1, 9 January 2020 (2020-01-09), pages 1710398
JESSICA MICHIE ET AL., CANCER IMMUNOL RES., vol. 7, no. 2, 2019, pages 183 - 192
PETER J HOUGHTON ET AL., PEDIATR BLOOD CANCER., vol. 58, no. 4, 2012, pages 636 - 639
MELISSA K BRUNCKHORST ET AL., CANCER BIOLOGY THERAPY., vol. 13, no. 9, 2012, pages 804 - 811
QIAN CAI ET AL., MED CHEM., vol. 54, no. 8, 2011, pages 2714 - 2726
NAKAZAWA T ET AL., ANTICANCER RES., vol. 40, no. 6, 2020, pages 3231 - 3237
MINSUNG KIM ET AL., PLOS ONE., vol. 13, no. 6, 2018, pages e0198347
YE WENDA, GUNTI SREENIVASULU, ALLEN CLINT T., HONG YOUJI, CLAVIJO PAUL E., VAN WAES CARTER, SCHMITT NICOLE C.: "ASTX660, an antagonist of cIAP1/2 and XIAP, increases antigen processing machinery and can enhance radiation-induced immunogenic cell death in preclinical models of head and neck cancer", ONCOIMMUNOLOGY, vol. 9, no. 1, 1 January 2020 (2020-01-01), XP093036636, DOI: 10.1080/2162402X.2019.1710398
ROY XIAO, CLINT T. ALLEN, LINDA TRAN, PRIYA PATEL, SO-JIN PARK, ZHONG CHEN, CARTER VAN WAES, NICOLE C. SCHMITT: "Antagonist of cIAP1/2 and XIAP enhances anti-tumor immunity when combined with radiation and PD-1 blockade in a syngeneic model of head and neck cancer", ONCOIMMUNOLOGY, vol. 7, no. 9, 2 September 2018 (2018-09-02), pages e1471440, XP055526649, DOI: 10.1080/2162402X.2018.1471440
"The non-peptidomimetic cIAP1/2 and XIAP antagonist ASTX660 promotes an anti-tumour immune response in T-cell lymphoma", EUROPEAN JOURNAL OF CANCER, vol. 138, no. Suppl. 2, 2020, pages S28, XP086321408, DOI: 10.1016/S0959-8049(20)31141-2
MASAHIRO TSUJI // KEISHI ADACHI, KOJI TAMADA: "R & D initiative : new drug modality “Designer cell" // The novel strategies for CAR-T cell therapy targeting solid cancers", EXPERIMENTAL MEDICINE, YODOSHA CO., LTD., JP, vol. 38, no. 17, Suppl., 1 November 2020 (2020-11-01), JP , pages 25 - 34, 107-121, XP009543530, ISSN: 0288-5514
HO SEN NAOKI: "9. CAR-T Cell Therapy", EXPERIMENTAL MEDICINE SPECIAL EDITION, JP, vol. 37, no. 15, 13 September 2019 (2019-09-13), JP, pages 164 (2556) - 169 (2561), XP009543529, ISSN: 0288-5514
JESSICA MICHIE, ET AL.: "Antagonism of IAPs Enhances CAR T-cell Efficacy", CANCER IMMUNOLOGY RESEARCH, AMERICAN ASSOCIATION FOR CANCER RESEARCH, US, vol. 7, no. 2, 1 February 2019 (2019-02-01), US , pages 183 - 192, XP055632337, ISSN: 2326-6066, DOI: 10.1158/2326-6066.CIR-18-0428
FERRARI NICOLA, WARD GEORGE, GEWINNER CHRISTINA, DAVIS MATTHEW P., JUELIGER SIMONE, SAINI HARPREET, MUNCK JOANNE, SMYTH TOMOKO, FE: "Antagonism of inhibitors of apoptosis proteins reveals a novel, immune response-based therapeutic approach for T-cell lymphoma", BLOOD ADVANCES, vol. 5, no. 20, 26 October 2021 (2021-10-26), pages 4003 - 4016, XP093036700, ISSN: 2473-9529, DOI: 10.1182/bloodadvances.2020003955
SCIENCE, vol. 242, 1988, pages 1038 - 1041
NATURE, vol. 338, 1989, pages 54454 - 384
MOLECULAR IMMUNOLOGY, vol. 34, no. 16-17, 1997, pages 1157 - 1165
NATURE MEDICINE, 23 December 2007 (2007-12-23), pages 1436
J IMMUNOL., vol. 162, no. 2, 1999, pages 897 - 902
MOL CANCER THER., vol. 17, no. 7, July 2018 (2018-07-01), pages 1381 - 1391
ONCOIMMUNOLOGY, vol. 9, no. 1, 9 January 2020 (2020-01-09), pages 1710398
JESSICA MICHIE ET AL., CANCER IMMUNOL RES., vol. 7, no. 2, 2019, pages 183 - 192
PETER J HOUGHTON ET AL., PEDIATR BLOOD CANCER., vol. 58, no. 4, 2012, pages 636 - 639
MELISSA K BRUNCKHORST ET AL., CANCER BIOLOGY THERAPY., vol. 13, no. 9, 2012, pages 804 - 811
QIAN CAI ET AL., MED CHEM., vol. 54, no. 8, 2011, pages 2714 - 2726
NAKAZAWA T ET AL., ANTICANCER RES., vol. 40, no. 6, 2020, pages 3231 - 3237
MINSUNG KIM ET AL., PLOS ONE., vol. 13, no. 6, 2018, pages e0198347
Attorney, Agent or Firm:
SAEGUSA & PARTNERS (JP)
Download PDF: